Anti-Human IL-2R alpha (CD25) (Basiliximab) - Dylight® 488 Biosimilar (IVMB0498)
- SKU:
- IVMB0498
Frequently bought together:
Description
| Product Name: | Anti-Human IL-2R alpha (CD25) (Basiliximab) - Dylight 488 |
| SKU: | IVMB0498 |
| Size: | 100 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | Hu107 |
| Target: | CD25 |
| Isotype: | Human IgG1κ |
| Host Species: | Human |
| Reactivity: | Human/Rhesus Monkey/Cynomolgus Monkey |
| Applications: | FC |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Active |
| Synonyms: | IL-2-RA; IL2-RA; TAC antigen; p55; CD25 |
| Product Concentration: | 0.2 mg/ml |
| Excitation Laser: | Blue Laser (493 nm) |
| Immunogen: | Human CD25 |
| Applications and Recommended Usage: | FC The suggested concentration for Basiliximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. |
| Antigen Distribution: | IL-2Rα is expressed on activated mature T and B lymphocytes, during early stages of thymocytes development, pre-B cells, and in activated CD4+ memory T-lymphocytes. |
| Formulation: | This DyLight 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Basiliximab. Basiliximab recognizes human CD25. This product is for research use only. |
| Additional Applications Reported In Literature: | IFIHC |
| Additional Reported Applications For Relevant Conjugates: | CyTOFWBB |
CD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2Rα. It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25. Anti-Human IL-2R alpha (CD25) (Basiliximab) utilizes the same variable regions from the therapeutic antibody Basiliximab making it ideal for research projects.
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Storage and Handling: | This DyLight 488 conjugate is stable when stored at 2-8°C.Do not freeze. |
| Research Area: | Biosimilars |
Related Products
VivoGenie Anti-IL-2R alpha / CD25 (Basiliximab) Biosimilar (IVMB0229)
€269 - €7,279
VivoGenie Anti-IL-2R alpha / CD25 (Basiliximab) Biosimilar (Fc Reduced) (IVMB0231)
€619
